Page 2 - Eclipse Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Print Erasca, a biotechnology company pursuing precision oncology treatments to “erase cancer,” became San Diego’s newest publicly traded company late last week, raising $300 million in an upsized initial public stock offering. The company, co-founded in 2018 by life sciences entrepreneur Dr. Jonathan Lim, becomes the 11 th local firm to go public so far this year. That’s approaching an annual record of 12 IPOs on U.S. markets for San Diego-based startups — with five months to go in 2021. Erasca sold 18.75 million shares at $16 per share. The stock began trading Friday on the Nasdaq...

Share this article Share this article Mountain View, Calif., March 5, 2021 /PRNewswire/ -- BioEclipse Therapeutics™ (BioEclipse), a private clinical-stage biopharmaceutical company with a proprietary platform for developing next-generation cancer immunotherapies, announced today the administration of the first dose of CRX100 to a volunteer in the ongoing Phase 1 clinical trial in patients with refractory solid tumors. The trial is a first-in-human study for CRX100, BioEclipse's lead investigational drug candidate, an intravenously delivered, multi-mechanistic therapy designed to target and ...

Share this article Share this article MOUNTAIN VIEW, Calif., Jan. 19, 2021 /PRNewswire/ -- BioEclipse Therapeutics™ (BioEclipse), a private clinical-stage biopharmaceutical company with a proprietary platform for developing next-generation cancer immunotherapies, announced today the initiation of patient enrollment at the HonorHealth Research Institute in Scottsdale, Ariz. for a Phase 1 dose-escalation trial to treat refractory solid tumors. The trial marks the first-in-human study of CRX100, an intravenously delivered agent designed to target and destroy multiple cancer types and address...

During Biotech Showcase Digital, registered conference participants will be able to watch a pre-recorded presentation by BioEclipse. Also, Dr. Contag will host virtual one-on-one meetings with registered investors and pharmaceutical and biotechnology companies via the conference's networking and scheduling platform, partneringONE®, to discuss BioEclipse's business and  highlight recent corporate achievements, as well as anticipated milestones in the clinical program for CRX100. BioEclipse has initiated an open-label, Phase 1 dose-escalation study to evaluate the safety, tolerability, and ph...